← Leaderboards
Andrew Saxon
Sixal Corporation
$486,656
Attributed
$686,656
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $286.7K · FY2012–20$500K$375K$250K$125K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$686,656 · 2
By mechanism
R43$686,656 · 2
Top collaborators
- Ke Zhang2 shared
Others in their field
Top investigators on “Future”
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Gary D Acton · University Of California-Davis$320,373,312
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$274,284,003
- Chanza Baytop · Westat, Inc.$271,217,917
- Everette D Joseph · Howard University$246,289,043
Research focus
FutureIn VivoDeveloped CountriesFood HypersensitivityIgg1In VitroAllergicCrosslinkEffective TherapyFoodHypersensitivityAntibodiesAllergic ResponseIncidenceBaseBasophilsCellsComplexAllergic DiseaseBiologicalBiological Response Modifier TherapyEffector CellAllergensMast Cell
Grant awards (3)
Safety and efficacy of an allergy therapeutic targeting FcERI bound IgE in human immune reconstituted mice.$286,656
R43 · FY2020 · AI · contact PI
Targeting surface-bound IgE as a novel allergy therapeutic$200,000
R43 · FY2013 · AI
Targeting surface-bound IgE as a novel allergy therapeutic$200,000
R43 · FY2012 · AI